Financière de Tubize SA (FTD)
Market Open
25 Mar, 07:05
XSTU 
€
139. 00
-2.4
-1.7%
€
- Market Cap
34.05 P/E Ratio
0.97% Div Yield
0 Volume
0 Eps
€ 141.4
Previous Close Day Range
139 139
Year Range
88.2 154.6
Earnings results expected in 29 days
Summary
FTD trading today lower at €139, a decrease of 1.7% from yesterday's close, completing a monthly decrease of -2.52% or €3.6. Over the past 12 months, FTD stock lost -1.84%.
FTD is not paying dividends to its shareholders.
The last earnings report, released on Mar 22, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Apr 25, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XBRU (EUR).
Want to track FTD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
FTD Chart
Loading, please wait...
Financière de Tubize SA (FTD) FAQ
What is the stock price today?
The current price is €139.00.
On which exchange is it traded?
Financière de Tubize SA is listed on XBRU.
What is its stock symbol?
The ticker symbol is FTD.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Apr 25, 2025.
Has Financière de Tubize SA ever had a stock split?
No, there has never been a stock split.
Financière de Tubize SA Profile
| Biotechnology Industry | Healthcare Sector | Eric Nys CEO | XSTU Exchange | BE0003823409 ISIN |
| BE Country | - Employees | 30 Apr 2024 Last Dividend | 17 Jun 2005 Last Split | - IPO Date |
Overview
Financière de Tubize SA operates as a mono holding company primarily focused on the biopharmaceutical sector, through its significant investment in UCB, a leading biopharma company based in Belgium. This strategic position allows Financière de Tubize SA to leverage the innovations and financial performance of UCB, aiming for sustained growth and value creation in the biopharmaceutical industry. The company's operational and strategic base in Brussels, Belgium, places it at the heart of Europe's biopharmaceutical hub, enabling close collaboration and strategic alignment with UCB.
Products and Services
The principal product and service offering of Financière de Tubize SA is centered around its investment portfolio, with a key focus on:
- Investment in UCB - As a mono holding company, Financière de Tubize SA's primary product is its stake in UCB, a global biopharmaceutical company. This investment encompasses capital allocation towards UCB's research, development, and commercialization of innovative therapies in areas such as neurology and immunology. Through this stake, Financière de Tubize SA participates in the pharmaceutical industry's dynamics, including the development of drugs and treatment solutions aimed at addressing significant unmet medical needs.
Contact Information
Address: Allée de la Recherche 60, Brussels, Belgium, 1070
Phone: 32 497 51 52 08
Website: https://www.financiere-tubize.be
2025 © Marketlog. All Rights Reserved.
